AI for Pharma in the UK: Where It Pays in 2026

A Head of Pharmacovigilance is measured first on one unforgiving number: the share of serious adverse event cases submitted inside the statutory 15-day window, inspection after inspection. A Head of Regulatory Affairs is measured on submission cycle time and dossier quality. Neither of them is measured on how much AI their function has bought. Yet both are being asked to absorb more volume on a lean team, and that is where much of the sector's AI investment will be won or wasted.

The volume is real. Around 1.77 million individual case safety reports were logged in the EU's EudraVigilance database in 2025 alone, with its cumulative total past 31 million records; UK holders carry their own version of that reporting burden domestically through the MHRA (European Medicines Agency). The commercial pressure is real too. The headline VPAG payment rate on newer branded medicines ran at 22.9% for 2025, and 83% of companies responding to a 2025 ABPI survey said payment rates directly influence their headcount decisions. The rate falls to 14.5% for 2026, a drop of more than a third, but the hiring caution it built in does not unwind overnight. More cases, more dossiers, lean teams.

That is the context every pharma AI decision now sits inside. Across the wider economy around 88% of enterprises use AI in at least one function, yet only around 6% report material impact on profit (McKinsey, The State of AI, November 2025). The gap is not a technology gap. It is a placement gap: AI deployed where it does not move a regulated number returns nothing. This guide maps where AI actually pays across UK pharma and biotech, from the pharmacovigilance clock to the submission dossier to trial recruitment, and which part of the DILR.AI stack belongs at each point. It is a planning map, not a build manual. The deep mechanics of turning clinical documents into structured data sit in our clinical document extraction guide, and the broader NHS and health picture in our guide to AI for healthcare; this hub holds the altitude above them.

This guide is shipped by the team behind the DATS consulting system, which places and governs AI inside regulated enterprises. It is the flagship line for pharma because it decides where AI belongs before anything is built, and governs it for inspection from the start. Or design the governance first with an AI operating model, audit-ready before anything ships.

Where does AI pay first across UK pharma and biotech?

AI pays first in UK pharma where a regulated clock is already running and the work is document assembly, not scientific judgement. That means pharmacovigilance case intake against the 15-day deadline, regulatory dossier drafting and cross-referencing, and the standing evidence a Good Pharmacovigilance Practice inspection will ask for. These are high-volume, rules-bound, auditable workloads, and exactly where capacity is short and the cost of a slip is a licence question, not a productivity one.

The order matters. A pharmacovigilance team on a statutory deadline feels the pain first and can measure relief fastest, so it is the natural first placement. Regulatory affairs follows, because dossier cycle time is a slower clock but a larger cost. The governance layer, the standing audit evidence and the operating model that ties them together, is not an afterthought bolted on at the end; it is what makes the first two placements defensible when an inspector arrives.

What does the 15-day pharmacovigilance deadline actually require?

Under the Human Medicines Regulations 2012, a marketing authorisation holder must report a serious suspected adverse reaction within 15 days of becoming aware of it, and a non-serious one within 90 days. The duty binds the holder, not its software vendor, and the 15-day clock runs on serious reactions wherever in the world they occur. The work is intake, triage, medical coding, narrative writing and submission, and the clock does not pause because volume rose or a post went unfilled.

This is where the distinction between a format and a deadline matters. The 15-day limit is a legal obligation on the holder under Part 11 of the Regulations; the ICH E2B standard many teams cite is only the electronic format for how a case is transmitted, not the thing that sets the clock. The 1.77 million cases EudraVigilance logged in 2025 show the scale of adverse-event reporting across the EU, and UK holders file their own cases to the MHRA on the same 15-day clock. AI helps here by compressing the hours between a case arriving and a coded, submittable draft existing, so the human reviewer spends the 15 days assessing rather than assembling.

What do MHRA good pharmacovigilance practice inspections keep finding?

MHRA inspections keep finding system failures, not scientific ones. In the 2021 to 2022 reporting period its Good Pharmacovigilance Practice inspectorate recorded 169 findings across 32 inspections: 6 critical, 72 major and 91 minor. The failures cluster in process, with risk management the single largest share and the quality management system next. Critical findings stayed rare, which tells you the exposure is rarely a wrong clinical call; it is an evidence trail that does not hold up.

The MHRA records that, in its own report, "the highest proportion of findings regardless of grading were related to risk management, comprising 32% (54/169 findings)", with the quality management system accounting for a further 25%, or 42 of 169. The practical reading is simple. Evidence assembled in the fortnight before an inspection surfaces the gap at the worst possible moment. Evidence maintained continuously, as a standing pack rather than a scramble, turns inspection readiness from a recurring fire drill into a report you can produce on any given morning. A standing pack also changes what an inspector sees: the audit trail, the version history and the proof behind each case are already assembled rather than reconstructed under time pressure, which is exactly the process maturity the findings above reward. That is a document and workflow problem, which is to say an AI-placeable one, long before it is a headcount problem.

What does it now cost to get one drug approved, and why does that put AI on documents?

The cost keeps rising, which is why the industry is looking hard at the cost of producing documents. The average cost to progress a drug from discovery to launch reached $2.67 billion in 2025, up from $2.23 billion in 2024, across the cohort of large biopharma companies Deloitte tracks. Excluding GLP-1 weight-loss medicines, the underlying return is only 2.9%. When the science is that expensive, the hours scientists spend formatting dossiers are the easiest cost to question.

That is the regulatory affairs problem in one line: highly paid scientific and regulatory staff working as document assemblers, formatting and cross-referencing submissions instead of reviewing them. Deloitte's 2025 analysis shows the headline return lifting on the back of GLP-1 blockbusters; strip those out and the economics behind the rest of the pipeline are far thinner. A submission dossier is a vast, structured, cross-referenced document set, and most of the labour in it is assembly and consistency, not judgement. AI that drafts, cross-references and checks a dossier against a template does not make the regulatory decision; it gives the regulatory reviewer back the hours the assembly was eating, which is where cycle time and cost per approved asset actually move.

The same logic runs through our AI execution office, which embeds senior practitioners to ship these placements into production rather than leaving them as slideware. Placement, not enthusiasm, is what separates the 6% from the rest.

Why do the new Clinical Trials Regulations matter to recruitment speed?

Because the UK has a recruitment problem and has just rewritten the rules around it. New UK Clinical Trials Regulations came into force on 28 April 2026, which the MHRA and the Health Research Authority describe as the largest package of reforms to the regime in over 20 years. They land on a system that had been losing ground, where enrolment onto publicly supported commercial trials had fallen sharply. Recruitment speed is now under fresh regulatory attention.

The numbers behind that decline are specific. Patients enrolled onto NIHR-supported commercial trials fell 44% between 2017-18 and 2021-22, from around 50,000 a year to around 28,000, and the UK initiated 394 commercial trials in 2021 against 471 in Spain (Lord O'Shaughnessy's 2023 review); the reforms themselves are set out in the gov.uk announcement. Reform plus a recruitment deficit puts a premium on the operational tempo of a trial: site coordination, participant scheduling, reminders and sponsor reporting. None of these is the science, and none is the regulatory decision; all of them are coordination work on a clock, which is where a voice agent or a scheduled agent workflow earns its place. In practice that is participant reminders, visit scheduling, intake of contact and availability details for the site team, and the status reporting a sponsor owes its monitors, each running to a template and a clock rather than to clinical discretion. The duty to run the trial correctly binds the sponsor, not the vendor supplying its scheduling tools, so the placement question is narrow: which coordination tasks can be automated without touching a clinical or eligibility judgement.

Where the DATS consulting system fits against a submission dossier

DATS, the AI consulting system from DILR.AI, fits by deciding what to place before it builds anything, and by governing each placement so an inspector could audit it from day one. It is a five-stage system, Discover and Diagnose, Prioritise and Place, Operating Model, Pilot to Production, and Scale and Run, delivered by senior practitioners who ship code rather than decks. Against a submission dossier, the diagnostic ranks where AI belongs and where it does not, and the operating model it designs covers governance, RACI and lifecycle, audit-ready by design.

The sequence is deliberate. The four-to-six-week Placement Diagnostic produces a ranked roadmap, so the first pharmacovigilance or regulatory placement is chosen on evidence rather than on which vendor demoed best. The Operating Model work, over six to ten weeks, sets the governance, the RACI and the lifecycle, and is audit-ready by design, which is the point that matters when the finding a GPvP inspection records is a process gap. The Execution Office then embeds delivery, with the production placements the client owns. Of the six enterprise solutions DATS runs on its AI solutions page, enterprise knowledge retrieval and evaluation and observability for production agents map most directly onto a regulated documentation stack built on the company's own Azure, AWS, Google Cloud, Databricks or Snowflake.

When does a governed PV and regulatory operations desk belong in case processing?

A governed operations desk belongs in case processing once the work is genuinely shared between people and software agents and every step has to be auditable. Cognibl, from DILR.AI, is a work-management platform where people and AI agents share one board. What makes it fit a regulated desk is its proof rule: a task reaches a done status only once a proof version is attached, and the database refuses the move without one.

In pharma that maps onto a PV and regulatory operations desk running literature surveillance, case intake, regulatory intelligence, submission assembly, trial-site coordination and QA evidence. The Cognibl work-management platform supplies the board and the proof gate; it does not ship those agents itself, its records are append-only and hash-chained, every write is attributed through the gateway, and its two AI flows summarise and flag but never decide. That matters when payment-rate pressure has already pushed safety teams to run lean: the point is not to remove the qualified people, it is to make a smaller team's output defensible, with the definition of done, the evidence behind it and every tool call attached to the work. The governed-desk pattern is set out in our guide to AI agent work management.

What can Dilr Mira extract safely from adverse-event documents?

Dilr Mira is a class of private clinical small language models from DILR.AI, around 3 billion parameters, that turn scans, lab reports and claim forms into source-grounded, schema-valid JSON on the customer's own hardware, so the data never leaves the building. For pharmacovigilance that is a precise and bounded role: extracting the structured fields a case draft needs from an unstructured source document. The output is a draft for a human reviewer, never an autonomous clinical or safety decision.

The commercial route into a regulated deployment runs through DATS rather than as a standalone purchase. The Mira-Q2 model is open on Hugging Face under an Apache-2.0 licence and runs on a CPU, which is what makes an on-premise, data-stays-put deployment practical for a safety team that cannot send documents to a shared cloud. The published scorecard is honest about its own limits: field-level accuracy is near perfect on held-out gold data and lower on general physician prose, a gap the model card states rather than hides. Applying that extraction specifically to adverse-event source documents is an application direction we treat as part of a DATS build, with the depth in our clinical document extraction guide, not a shipped pharmacovigilance product.

How the six DILR.AI lines map onto UK pharma

Not every line applies, and saying so is part of an honest map. A hub that claimed all six lines fit every sector would be selling, not mapping. For UK pharma and biotech the stack divides cleanly into a lead, three secondary roles, one candidate and one that does not apply.

DATS leads, and our enterprise AI consulting guide sets out the method in full. Dilr Voice is secondary: it runs a multi-agent phone line in 30-plus languages, responds in under 500 milliseconds on DILR's own measurement, routes with warm transfer to a human with full context, and keeps a full audit trail on every call, which suits a medical information or adverse-event intake line where every call must be logged; our enterprise voice AI guide covers the architecture. Cognibl is the candidate for the operations desk. Dilr Mira is secondary for extraction, covered in the open models guide. Dilr Academy is secondary as the training step: its AI tutor builds courses on demand, so teams can learn to govern what they deploy, with the method in our AI teacher buyer's guide. DILR Studio, the promptless content platform, does not apply here, with no named pharma use case. The pattern across every sector sits in our AI by industry guide.

What is the best way to place AI in a regulated pharma operation?

The best approach in 2026 is to place AI on one bounded, deadline-bound workload first, prove it against a regulated number, and govern it before scaling, rather than running a portfolio of ungoverned pilots. For a pharmacovigilance or regulatory team that means starting with case intake or dossier assembly, measuring 15-day compliance or submission cycle time, and building the audit evidence into the workflow from day one. That order is what turns a pilot into a defensible production system.

The large consultancies, Accenture, Deloitte, PwC, EY, KPMG and specialists such as Faculty, all compete for this transformation work, and for a board-level programme spanning the whole estate several of them will be the right call. Where a senior-practitioner, placement-first approach wins is the regulated middle: a team that needs a governed production placement running in weeks, not a multi-year transformation, and that cares more about an audit-ready operating model than a large change programme. Where a buyer needs organisation-wide change management and a global delivery footprint, a large firm is the better fit, and an honest map says so. The decision is less about the vendor than about whether the first placement is chosen on evidence and governed from the start.

Does adverse event and regulatory data have to stay inside the company?

For a pharma safety or regulatory team handling adverse-event data, usually yes, and the architecture should assume it. The operating model DATS designs decides the deployment pattern per workload. Where a voice line is involved, Dilr Voice offers dedicated tenancy and data residency on Google Cloud; Dilr Mira runs extraction on the customer's own hardware, so documents never leave the building. On-premise is a first-class option wherever data cannot move.

Can AI make a pharmacovigilance or regulatory decision?

No, not on a DILR deployment, and the design keeps it that way. These tools draft, extract, triage and assemble; a qualified person makes the call. A case narrative is a draft for medical review, an extracted field a draft for verification, and a Cognibl agent flags but does not decide. The regulatory duty, whether the 15-day pharmacovigilance clock or a clinical trial approval, binds the marketing authorisation holder or the sponsor, and that accountability stays with a named human.

To go deeper from here, read the enterprise AI consulting guide, design the governance with an AI operating model, embed delivery through an AI execution office, or see every sector in the industries hub.

Written by the Dilr.ai engineering team, practitioners who ship enterprise AI in production. Follow us on our LinkedIn page for shipping notes, or subscribe via the RSS feed.